What was new in indolent NHL at #ASCO20 and EHA?

Following this year's American Society of Clinical Oncology (ASCO) Annual Meeting and during the 25th Congress of the European Hematology Association (EHA), the Lymphoma Hub spoke to Nathan Fowler, MD Anderson Cancer Center, Houston, US. We asked: What was new in indolent non-Hodgkin lymphoma at ASCO and EHA 2020?

Nathan Fowler highlights abstracts of particular interest from ASCO, including a study evaluating the chimeric antigen receptor T-cell treatment, axicabtagene ciloleucel, for indolent non-Hodgkin lymphoma, a long-term follow up of the GALLIUM trial, and the interim analysis of the MAGNIFY trial. Nathan Fowler also outlines abstracts to watch from EHA, including studies evaluating zanubrutinib for the treatment of marginal cell lymphoma and those investigating the PI3-kinase delta inhibitor, ME-401, for the treatment of relapsed or refractory disease.